Company: MBIO
Filing Date: 2025-02-11
Form Type: 8-K
Source: 0001104659-25-011517
Chunk: 0

Company: MUSTANG BIO, INC.
Filing Date: 2025-02-11
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item 1.01.      Entry Into a Material Definitive Agreement.  

Securities Purchase
Agreement

On February 5, 2025,
Mustang Bio, Inc. (the “ Company”) commenced a best efforts public offering (the “ Offering”) of an aggregate of
(i) 495,000 shares (the “ Shares”) of its common stock, par value $0.0001 per share, (ii) pre-funded warrants (the “ Pre-Funded
Warrants”) to purchase up to an aggregate of 2,162,807 shares of common stock (the “ Pre-Funded Warrant Shares”), (iii)
Series C-1 warrants (the “ Series C-1 Warrants”) to purchase up to an aggregate of 2,657,807 shares of common stock (the “ Series
C-1 Warrant Shares”), and (iv) Series C-2 warrants (the “ Series C-2 Warrants,” and together with the Series C-1 Warrants,
the “ Warrants”) to purchase up to an aggregate of 2,657,807 shares of common stock (the “ Series C-2 Warrant Shares,”
and together with the Series C-1 Warrant Shares, the “ Warrant Shares”). Each Share or Pre-Funded Warrant was sold together
with one Series C-1 Warrant to purchase one share of common stock and one Series C-2 Warrant to purchase one share of common stock. The
combined public offering price for each Share and accompanying Warrants was $3.01, and the combined public offering price for each Pre-Funded
Warrant and accompanying Warrants was $3.0099. The Pre-Funded Warrants have an exercise price of $0.0001 per share, are exercisable immediately
upon issuance and will expire when exercised in full. Each Warrant has an exercise price of $3.01 per share and will be exercisable beginning
on the effective date of stockholder approval of the issuance of the Warrant Shares (the “ Warrant Stockholder Approval”).
The Series C-1 warrants will expire five years from the Warrant Stockholder Approval and the Series C-2 warrants will expire twenty-four
months from the Warrant Stockholder Approval.

The net proceeds of the
Offering, after deducting the fees and expenses of the Placement Agent (as defined below), described in more detail below, and other offering
expenses payable by the Company, but excluding the net proceeds,